BBV STI Surveillance and Research Programme: Surveillance for Hepatitis B Indicators
A key aspect of Australia’s National Hepatitis B Strategy 2014-2017 is the identification of specific measurable aims and targets, including increasing the proportion of people living with chronic hepatitis B (CHB) who have been diagnosed, increasing treatment uptake in those affected, and reducing the burden of attributable morbidity and mortality associated with the disease. Measuring the progress towards the objectives and targets of the National Strategy will allow for identification of priority areas in order to shape the public health and policy response to hepatitis B in Australia.
To develop disease burden estimation and mathematical modelling approaches to inform the surveillance, monitoring and evaluation of progress towards achieving the objectives of the Second National Hepatitis B Strategy 2014-2017, reporting against Hepatitis B Indicators in the National Blood-borne Viruses and Sexually Transmissible Infections Surveillance and Monitoring Plan 2014-2017.
Tasks and Outputs
Proposed tasks include:
- Number of people living with chronic hepatitis B in Australia
- Proportion of people living with chronic hepatitis B in Australia who have been diagnosed
- Proportion of people living with chronic hepatitis B who are dispensed drugs for the treatment of hepatitis B through the Pharmaceutical Benefits Scheme
- Burden of disease attributable to chronic hepatitis B in Australia
Indicator data estimate outputs will be incorporated into The Kirby Institute Annual Surveillance Report and the National Viral Hepatitis Mapping Project Reports, along with supporting interpretive and methodological information.
WHO Collaborating Centre for Viral Hepatitis, VIDRL, The Doherty Institute
Project lead: Prof Benjamin Cowie
Nicole Romero (03) 9342 9370 [email protected]
Health Surveillance Fund, Australian Government Department of Health